TechnoPulm
Disruptive Diagnostic Tool for Pulmonary-Function Testing
Company Overview
Snapshot
Founded in March 2021 by Shabty Negry and Igor Krivits, TechnoPulm operates with 1–10 employees. The company has raised $2 million across two funding rounds from one investor. In October 2024, TechnoPulm secured $2 million to advance its handheld device for comprehensive lung function tests.
Business overview
TechnoPulm is developing an advanced handheld diagnostic device designed for comprehensive pulmonary function testing (PFT) and accurate lung volume measurements (LVM). The company's patented TechnoPulm system (STS) provides spirometry and plethysmography capabilities in both clinical and home settings, aiming to eliminate the need for hospital visits for such tests. It serves the digital healthcare and medical devices industries, focusing on patients and providers within the Health Tech & Life Sciences sector.
Strategic signal
In October 2024, TechnoPulm raised $2 million to further develop its handheld device for full lung function tests. This funding underscores investor confidence in the company's innovative approach to remote pulmonary diagnostics and its potential to disrupt traditional testing methods, signaling a strong focus on product development and market entry in the near future.
Company Intelligence Q&A
- What is TechnoPulm's core product?
- TechnoPulm's core product is the TechnoPulm system (STS), a patented handheld device that performs comprehensive pulmonary function testing (PFT) and accurate lung volume measurements (LVM) using spirometry and plethysmography.
- When was TechnoPulm founded and by whom?
- TechnoPulm was founded in March 2021 by co-founders Shabty Negry, who serves as CEO, and Igor Krivits, the CTO.
- What significant funding did TechnoPulm receive recently?
- In October 2024, TechnoPulm raised $2 million to support the development of its handheld device for comprehensive lung function tests.
- What is the strategic goal of TechnoPulm's diagnostic device?
- TechnoPulm aims to provide a remote telemedicine platform for comprehensive patient examinations, thereby eliminating the need for patients to visit hospitals for lung function tests.
- What was the nature of the funding received in May 2024?
- In May 2024, TechnoPulm received funding from the Israel Innovation Authority, which is a governmental grant for proof-of-concept development.